Dario Tuccinardi on Obesity as Cardiovascular Treatment Target
Dario Tuccinardi, Assistant Professor in Endocrinology at The Bio-Medical University of Rome, shared on LinkedIn:
”Obesity is no longer just a cardiovascular risk factor. It is a cardiovascular treatment target.
Obesity and visceral adiposity actively shape cardiovascular disease, through inflammation, altered myocardial energetics, and diagnostic distortion.
Yet in daily practice, patients with obesity are still affected by clinical bias: symptoms are under-recognized, biomarkers misinterpreted, and treatment decisions delayed or diluted.
Our review argues for a double shift.
First: therapeutic.
Modern anti-obesity pharmacotherapy, especially GLP-1 receptor agonists and dual-incretin agents, extends beyond weight loss.
These drugs improve endothelial function, reduce inflammation, optimize myocardial metabolism, and now demonstrate cardiovascular event reduction even in people with obesity without diabetes.
Second: cultural and clinical.
Cardiologists must be supported in overcoming weight-related bias—moving beyond BMI, recognizing visceral obesity, correctly interpreting biomarkers, and confidently treating obesity as part of cardiovascular care rather than deferring it.
Treating obesity is no longer optional.
It is evidence-based cardiovascular medicine.
Weight loss is not about weight.
It’s about outcomes.”
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 3, 2026, 08:53Jamie’s Journey Through a Decade with Immune Thrombocytopenia – ITP Support Association
-
Sep 3, 2026, 08:00Beth Meneley: When Transfusion Is Not an Option – HBOT for Exceptional Blood Loss Anemia
-
Sep 3, 2026, 06:27Seyed Mehrab Safdari: Unmasking Factor VII Padua to Prevent Unnecessary Therapy and Thrombotic Risk
-
Sep 3, 2026, 04:09Pedro Perez: Are We Entering a New Era in the Treatment of Intermediate-High-Risk PE?
-
Sep 3, 2026, 04:01Marianne Yee: Supporting Families and Transformative Therapies in Sickle Cell Disease
-
Sep 3, 2026, 03:51Strengthening Bleeding Disorders Care in New Zealand – WFH
-
Sep 3, 2026, 03:42Nathan Connell: FDA Approves Rusfertide for Polycythemia Vera
-
Sep 3, 2026, 03:28Katrina Snow: Learning More About Sickle Cell Disease This September
-
Sep 3, 2026, 01:19Himanshu Aggarwal: 1 mg/kg/d Thalidomide Non-Inferior to Standard Dose in Transfusion-Dependent Thalassemia